Vertex Pharmaceuticals (VRTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX)

VRTX 437.17

+0.6%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (478)	2/22/2001 12:05:08 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 1169

VX-497 It appears the stock is getting hit for a lack of statistical significance in treating HCV. The study consisted of 50 people and lasted 28 days. The company gave wider variability of response among the patients as a reason that statistical significance was not achieved. In the light of the long term treatment required where a combo of ribavirin and Intron A is used and the various genotypes of HCV (Type 1 being predominant in the US and the most unresponsive to current treatment) the company explanation makes sense to me. Am I just being simple? Your science challenged lawyer, ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next